Skip to content

Inventory Current at other companies

Cricut, Inc. logo
Cricut, Inc.CRCT
$106.04M-7.3%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$87.06M
Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.58B+15.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$26.19M+109%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$14.51M+1,144%
Viatris logo
ViatrisVTRS
$3.93B-4.1%

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$1.05B-32.6%
Enterprise value$1.12B-26.0%
P/S10.6×-5.4×

Profitability

See full
Operating margin-204.5%
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept spry:InventoryCurrent.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s inventory current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s inventory current?
ARS Pharmaceuticals, Inc. (SPRY) reported inventory current of $8.82M in Q1 2026.
What does inventory current mean?
This metric represents the aggregate value of raw materials, work-in-progress, and finished pharmaceutical products held by the company. It serves as a critical indicator of supply chain readiness and the company's ability to meet market demand for its therapeutic products. Monitoring this balance helps assess potential obsolescence risks and the efficiency of inventory turnover cycles.